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Multidrug transporter MRP4/
ABCC4 as a key determinant 
of pancreatic cancer aggressiveness
A. Sahores1, A. carozzo1, M. May1, N. Gómez1, n. Di Siervi1, M. De Sousa Serro1, A. Yaneff1, 
A. Rodríguez‑González2, M. Abba3, C. Shayo2 & c. Davio1*
Recent findings show that MRP4 is critical for pancreatic ductal adenocarcinoma (PDAC) cell 
proliferation. Nevertheless, the significance of MRP4 protein levels and function in PDAC progression 
is still unclear. The aim of this study was to determine the role of MRP4 in PDAC tumor aggressiveness. 
Bioinformatic studies revealed that PDAC samples show higher MRP4 transcript levels compared 
to normal adjacent pancreatic tissue and circulating tumor cells express higher levels of MRP4 than 
primary tumors. Also, high levels of MRP4 are typical of high-grade PDAC cell lines and associate with 
an epithelial-mesenchymal phenotype. Moreover, PDAC patients with high levels of MRP4 depict 
dysregulation of pathways associated with migration, chemotaxis and cell adhesion. Silencing MRP4 
in PANC1 cells reduced tumorigenicity and tumor growth and impaired cell migration. Transcriptomic 
analysis revealed that MRP4 silencing alters PANC1 gene expression, mainly dysregulating pathways 
related to cell-to-cell interactions and focal adhesion. Contrarily, MRP4 overexpression significantly 
increased BxPC-3 growth rate, produced a switch in the expression of EMT markers, and enhanced 
experimental metastatic incidence. Altogether, our results indicate that MRP4 is associated with a 
more aggressive phenotype in PDAC, boosting pancreatic tumorigenesis and metastatic capacity, 
which could finally determine a fast tumor progression in PDAC patients.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies, due to its late diag-
nosis, inherent resistance to treatment and early  dissemination1. This type of tumor is expected to become the 
second leading cause of cancer mortality by the year 2030 and has limited therapeutic  options2. Even after the 
development of new targeted agents and the use of multiple therapeutic combinations, there is no clear benefit for 
this disease. Thus, there is an unmet need to propose novel strategies to target PDAC and improve its prognosis.
Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) is a member of the ATP-binding cassette (ABC) 
protein family that act mainly as molecular transporters and as such, are key participants in the emergence of 
multidrug resistance in  cancer3. Also, MRP4 endogenous substrates may participate in signaling transduction, 
cell proliferation, metabolism, survival, apoptosis, senescence, exocytosis and  endocytosis4–6. In addition, MRP4 
actively affects tumorigenesis and has been associated with progression in numerous types of cancers, including 
blood, brain, colon, liver, lung, and  prostate7 but has only been briefly described in pancreatic  cancer8.
We have recently proved that MRP4 is a key participant in PDAC cell proliferation, mainly by regulating 
cAMP  efflux9. We described that MRP4 mRNA and protein levels inversely correlate with the degree of dif-
ferentiation of pancreatic cancer cell lines and that PDAC patients with high expression of MRP4 tend to have 
a shorter overall survival compared to patients with low MRP4 expression. These findings suggest that MRP4 
has tumor promoting functions and that high levels of MRP4 expressed selectively in human pancreatic tumor 
tissues may contribute to the development of high-risk pancreatic cancer.
Using available whole genome expression datasets, in this study we sought to validate our hypothesis that 
MRP4 is associated with a more aggressive phenotype in PDAC. We also explore whether MRP4 influences 
PDAC tumor growth and its ability to spread, including cell migration and in vivo tumor dissemination studies 
in pancreatic cancer models and immunosuppressed mice. Our findings will help us determine the role of MRP4 
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in PDAC tumor biology and set the basis to further validate this transporter as a potential prognosis biomarker 
and/or therapeutic target for PDAC.
Results
Bioinformatic analysis of MRP4 differential expression in PDAC samples, PDAC cell lines and 
CTC from PDAC patients. To investigate MRP4 expression in human pancreatic cancer, we performed 
a differential expression analysis comparing PDAC and normal pancreatic tissue using several online data-
sets. GEPIA analysis showed a significant MRP4 upregulation in tumor samples compared to normal tissues 
(Fig. 1a). Similarly, the expression data from three different datasets from the Gene Expression Omnibus (GEO: 
GSE15471, GSE62452, and GSE71729) revealed higher MRP4 transcript levels in PDAC specimens relative to 
matching normal samples (p < 0.001 and p < 0.05; Fig. 1b). Bioinformatic analysis of GSE71729 dataset also evi-
denced that MRP4 is upregulated in 17 established pancreatic cancer cell lines compared to tumor and peritu-
mor samples (p < 0.001), suggesting that elevated expression of MRP4 is associated with the process of carcino-
genesis and may confer an adaptive phenotype to cells growing in culture.
In agreement with recent studies from our  laboratory9, we confirmed that MRP4 transcript levels inversely 
correlate with PDAC cell line differentiation grade (GSE64557  dataset10; n = 9; Fig. 1c). Low-grade tumors tend to 
have better prognosis and highly express adhesion and epithelial genes, while high-grade tumors are associated 
with a worse prognosis and show high expression of mesenchymal  genes11. In line with this, we further explored 
vimentin and E-cadherin expression in the same panel of PDAC cell lines, as both proteins are associated with 
the process of epithelial-mesenchymal transition (EMT). The bioinformatic analysis evidenced that high-grade 
PDAC cell lines express high levels of vimentin and low levels of E-cadherin, whereas the opposite is observed 
in low-grade PDAC cell lines. In addition, high-grade PDAC cell lines depict EGFR upregulation, which has 
been associated with advanced stage, metastatic disease, and poor differentiation and survival in pancreatic 
 adenocarcinoma12,13. Interestingly, a significant inverse correlation was observed between MRP4 and GATA6 
expression levels (p < 0.05; Fig. 1d), which has been recently described to inhibit EMT and tumor dissemination in 
pancreatic  cancer14. Collectively, our observations indicate that high MRP4 transcript levels could be linked to the 
maintenance of a mesenchymal phenotype and determine a poorer outcome in patients with pancreatic cancer.
As reported in Carozzo-Yaneff et al., we used the gene expression profile obtained from TCGA-PAAD RNAseq 
dataset (n = 178; UCSC Xena), and classified it into two groups of patients according to low (LE; 24/178) or high 
(HE; 48/178) MRP4 mRNA  levels9. Taking in consideration we had already described that MRP4 HE patients 
tend to have shorter overall survivals compared to MRP4 LE patients, we further assessed the differential gene 
expression between both groups. We now identified 720 genes differentially expressed between HE and LE 
MRP4 carcinomas (FDR < 0.05; Fold changes > 2; Fig. 1e). Ninety three % of the identified transcripts (671/720) 
were upregulated in HE tumors, while only 6.8% (49/720) were downregulated genes (Supplementary Table S1). 
Interestingly, functional enrichment analysis of dysregulated transcripts revealed specific bioprocesses charac-
teristic of MRP4 HE tumors; strongly associated with the regulation of cell migration (p = 3.65e−8), chemotaxis 
(p = 1.21e−7), and cell adhesion (p = 1.98e−7), consistent with a mesenchymal and aggressive phenotype. Fur-
thermore, we also identified a high association between GPCR (p = 6.45e−7), PI3K-Akt-mTOR (p = 8.29e−7), 
and Rap1 (p = 4.66e−8) signaling pathways with MRP4 expression in PDAC cases (Fig. 1f). The dysregulation of 
these genes and processes could result in the pathogenesis or progression of pancreatic cancer.
Circulating tumor cells (CTC) are key for metastatic spreading as they detach from the primary tumor mass 
and survive in distant organs. In this sense, we took advantage of the public GSE18670 whole genome microarray, 
consisting of CTC isolated from the blood of six patients who underwent surgery for  PDAC15. We observed that 
MRP4 transcript levels are upregulated in CTC compared to primary tumor cells of PDAC patients (p < 0.001; 
Fig. 1g). This observation suggests that MRP4 upregulation may confer tumor cells a greater ability to survive 
in circulation, enhancing their migratory and metastatic phenotype.
Effect of MRP4 silencing in PANC1 xenograft growth and cell migration. With the intention of 
evaluating the biological effect of MRP4 modulation upon tumor aggressiveness, we carefully selected two cell 
lines with dissimilar MRP4 protein levels and differentiation grade: PANC1 cells depict high levels of MRP4 and 
are considered poorly differentiated, whereas the moderately differentiated BxPC-3  cells16 express intermedi-
ate MRP4 levels. We have recently established that MRP4 silenced PANC1 clones exhibit a slower proliferation 
curve compared to scramble cells and that BxPC-3 MRP4-overexpressing clones proliferate more than mock 
 cells9.
In order to assess the relevance of MRP4 inhibition on tumor aggressiveness, we first inoculated nude mice 
with scramble cells and the two MRP4-silenced PANC1 clones (MRP4sh1 and sh2), and then evaluated tumor 
incidence and growth. As described in our recent publication, MRP4sh1 cells express lower MRP4 levels than 
MRP4sh2 cells (49% and 69% compared to scramble cells, respectively)9. Silencing MRP4 strongly reduced 
tumor incidence: 91% (10/11) for scramble cells, 55% (6/11) for MRP4sh2 cells and 27% (3/11) for MRP4sh1 
cells (Fig. 2a). Linear regression of the tumor growth curves evidenced that all silenced PANC1 xenografts 
grew significantly slower than the scramble cells (p < 0.001), and that MRP4sh1 tumors grew even less than 
MRP4sh2 tumors. Moreover, MRP4sh xenografts which did grow, displayed smaller tumor masses compared 
to the scramble cell line (p < 0.001). Our results reveal that silencing MRP4 significantly disrupts PANC1 tumor 
formation and growing capacity.
Histological analysis revealed that all xenografts displayed a non-differentiated pattern, as cells do not form 
any kind of glandular structure (Fig. 2b). Tumors are composed by solid tumor sheets of atypical cells with very 
little stromal septa, like PANC1 parental  tumors17. The xenografts show moderate amounts of blood vessels, 
perineural invasion and infiltrating margins. In accordance with the observed growth rate, silenced xenografts 
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Figure 1.  Bioinformatic analysis of MRP4 differential expression in PDAC samples, normal/adjacent pancreatic 
tissue, PDAC cells lines and circulating tumor cells from PDAC patients. (a) Differential expression of MRP4 
according to the Gene Expression Profiling Interactive Analysis (GEPIA) database using TCGA PAAD tumor 
data and matched data of normal tissue from TCGA. (b) Comparative analysis of MRP4 mRNA expression from 
three different gene expression datasets comprising pancreatic normal tissue and their paired PDAC samples 
(GSE15471 and GSE62452), as well as PDAC cell lines (GSE71729). (c) MRP4, vimentin, E-cadherin, and EGFR 
transcript levels in a panel of 9 pancreatic cancer cell lines systematically arranged from the less aggressive (Lo-
G) to the more aggressive (Hi-G) phenotypes (GSE64557). (d) Inverse correlation between MRP4 and GATA6 
expression levels in the 9 pancreatic cancer cell lines from the beforementioned dataset. (e) Heatmap showing 
differentially expressed genes in MRP4 LE and HE PDAC samples performed with MultiExperiment Viewer 
(MeV). Differentially expressed genes were identified based on a log2(fold change) ≥ 1 and an FDR ≤ 0.05. 
Hierarchical clustering was based on Pearson correlation coefficients. (f) Functional enrichment analysis of 
differentially expressed genes showing pathways associated with MRP4 expression (p-adjusted < 0.05). See 
Supplementary Table S1. (g) Negative depletion fluorescence activated cell sorting (FACS) was used to enrich 
for CTC from the blood of 6 patients who underwent surgery for PDAC (GSE18670). Positive 7-amino-
actinomycin D viability and negative CD45 and CD34 cells were identified as CTC. We considered mRNA levels 
of ABCC4 1552918 isoform an indicator of MRP4 expression levels. Statistics: t-test ***p < 0.001 and *p < 0.05.
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Figure 2.  MRP4 silencing reduces tumor growth and tumorigenicity in PANC1 xenografts. Swiss nude mice were 
subcutaneously injected either with PANC1-MRP4sh2, PANC1-MRP4sh1 clones or PANC1-scramble as a control. 
Each group contained 8–11 animals and the data shown represents measurements of one of two experiments. (a; 
left) Tumors were measured with a caliper three times a week for 32 days post-inoculation and tumor volume was 
calculated as described in “Materials and Methods”. (a; middle) Representative pictures of the dissected xenografts 
of each group at the end of the experiment. (a; right) Tumor weight was measured with a scale after dissection. 
(b) PANC1-scramble, PANC1-MRP4sh2 and PANC1-MRP4sh1 xenografts were processed for histological (H&E 
staining), MRP4, Ki67, and EGFR immunostaining evaluation. Nuclei were counterstained with hematoxylin. 
Representative images are shown. Cell number per field, proliferative index, MRP4 and EGFR scores were determined 
by H&E, Ki67, MRP4, and EGFR staining respectively, and are shown as bar plots (right). Data is shown as 
mean ± SEM. Statistics: Linear regression and one-way ANOVA followed by Tukey’s t-test. ***p < 0.001 and **p < 0.01.
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display a smaller number of viable epithelial neoplastic cells (quantified as cell number per field; p < 0.01) and an 
increased amount of stromal component, both evidenced by hematoxylin and eosin (H&E) and Pan-CK staining 
(data not shown). Immunostaining for MRP4 confirmed that MRP4sh1 and MRP4sh2 xenografts are indeed 
silenced, as they display almost no MRP4 staining compared to scramble tumors (p < 0.001). Proliferation rate, 
determined by Ki67 immunostaining, and EGFR score were consistent with MRP4 expression levels, showing 
a diminished proliferation index and EGFR immunostaining in silenced tumors compared to scramble tumors 
(p < 0.001 and p < 0.01, respectively; Fig. 2b).
Further, we assessed whether MRP4 silencing also affected PANC1 migratory ability in culture. The wound-
healing assay showed that MRP4 downregulation significantly impaired the migratory phenotype of PANC1 cells 
(p < 0.05; Fig. 3). These results suggest that MRP4 determines PDAC aggressiveness per se and that its expression 
levels may correlate with PDAC metastatic potential.
Impact of MRP4 silencing on cell processes that may determine PDAC level of aggressive‑
ness. To investigate how MRP4 may determine the level of aggressiveness in PDAC, we performed an 
RNAseq analysis of PANC1, PANC1-scramble and PANC1-MPR4sh2 transcriptomes. Unsupervised analy-
sis revealed that all three cell lines are readily separated from each other and that biological replicates cluster 
together (Fig. 4a). As expected, MRP4sh2 cells display downregulation of the MRP4 gene (ABCC4) compared 
to control (scramble and parental PANC1) cells (Fig. 4b). By performing a differential expression analysis com-
paring MRP4sh2 and scramble cells, we were able to identify a gene set of 269 (166 upregulated and 103 down-
regulated; FDR < 0.05; Fold changes > 2) transcripts that showed significant expression changes when MRP4 was 
suppressed (Fig. 4c, Supplementary Table S2).
Interestingly, functional enrichment analysis revealed that cell surface interactions (p = 1.88e−7), focal adhe-
sion (p = 5.70e−5), and extracellular matrix interactions (p = 1.79e−3), appear to be among the most dysregulated 
processes in MRP4sh2 cells (p < 0.05; Fig. 4d,e). This could compromise the migratory and invasive ability of 
PANC1 cells. Differential expression of genes related to the Arf6, (p = 1.07e−2), Plexin-D1 (p = 1.07e−2) and Wnt 
(WNT5B: p = 5.14e−10, NRARP: p = 1.59e−6, and PRICKLE2: p = 4.73e−9, among other transcripts) cascades may 
also affect cell proliferation, differentiation and invasion, all processes associated with EMT and CTC phenotypes. 
Interestingly, IGFBP2, described as a pivotal regulator of an EMT axis in  PDAC18 is downregulated in MRP4sh2 
cells compared to scramble cells (p = 6.03e−5). Notably, IGFBP2 promotes invasion and metastasis of PDAC cells 
through NF-κB pathway, which is also altered in MRP4-silenced cells (Supplementary Table S2). In a similar way, 
the transcription factor GATA5 is also underexpressed (p = 3.04e−5; Supplementary Table S3, showing the top 
10 down- and upregulated transcripts) and, as a key enhancer of histone marks associated with PDAC progres-
sion and dissemination in vivo19, may contribute to the resulting less aggressive phenotype of MRP4sh2 cells.
In coherence with data illustrated in Fig. 1, modulation of MRP4 levels also reverberates in GPCR signaling 
pathways (p = 2.80e−2). The GPCR-associated dysregulated genes in MRP4sh2 cells include: EREG, GAL, IL11, 
INHBB, JAG2, NDP, RGS4, VEGFA and WNT5B, among others (Supplementary Table S2). Although PI3K-Akt 
signaling pathway does not emerge as one of the main altered pathways upon MRP4 suppression, several genes 
related to this cascade are significantly modulated (Down: PPP2R3, VEGFA, EREG, LAMB1, and Up: LAMC3, 
COL6A2, COL4A5; Fig. 4e).
Altogether, these findings indicate that MRP4 silencing alters gene expression which may explain the slow 
proliferation and poor migratory capacity of MRP4sh cells. The data also highlights many of the signaling path-
ways which are dysregulated in PDAC tumor samples with dissimilar levels of MRP4 and points to an association 
between low levels of the transporter and a good prognosis in pancreatic cancer.
Effect of MRP4 overexpression in BxPC-3 xenograft growth and experimental metastasis. We 
then analyzed the xenograft growth curves of BxPC-3 clones in NSG mice and observed that MRP4 overexpres-
Figure 3.  MRP4 silencing impairs cell migration in PANC1 clones. (a) PANC1-scramble, PANC1-MRP4sh1 
and PANC1-MRP4sh2 cell migration was assessed by closure of the wound. The area of the scratch was 
measured at T:0 h and T:48 h in all cell lines, and % reduction of initial scratch area was compared as described 
in “Materials and methods”. Data is shown as mean ± SEM of six measurements and the experiment was 
performed three times. (b) Representative images of a wound at starting point (T: 0 h), and PANC1-scramble, 
PANC1-MRP4sh1 and PANC1-MRP4sh2 cell migration into the wound at 48 h post scratch are shown. Wound 
areas are delimited in black. Statistics: One-way ANOVA followed by Tukey’s t-test. **p < 0.01.
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Figure 4.  MRP4 silencing reprograms gene expression, mainly dysregulating pathways related to cell surface interactions, 
focal adhesion, and extracellular matrix remodeling. (a) Unsupervised clustering of PANC1 cell lines based on transcriptomic 
profiles. (b) Box plot of MRP4 (ABCC4) mRNA expression between PANC1 cell lines, showing MRP4 is underexpressed in 
MRP4sh2 compared to control (PANC1 and PANC1-scramble) cells. (c) Volcano plot representing the significance (− Log10 
p-value) and magnitude of transcript change (Log2FC) in scramble and MRP4sh2 cells. The red dots represent significantly 
upregulated transcripts and the green dots represent downregulated transcripts upon MRP4 silencing (FDR < 0.05; Fold 
Changes > 2). (d) Functional enrichment analysis were performed using the Enrichr resource (https ://amp.pharm .mssm.
edu/Enric hr) and InnateDB (https ://www.innat edb.com) based on the list of dysregulated transcripts between scramble and 
MRP4sh2 cells (FDR < 0.05; Fold changes > 2). See Supplementary Table S2. (e) Heatmap showing differentially expressed 
genes related to the enriched signaling pathways. Hierarchical clustering was based on Pearson correlation coefficients.
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sion increases tumor burden, as BxPC-3-MRP4 xenografts display higher growth slopes and are heavier than 
mock tumors (Fig. 5a). In agreement with previous histological  reports20, inoculated BxPC-3 clones form mod-
erately differentiated adenocarcinomas, with traces of mucin, thin stromal tracts and are more comparable to 
pancreatic normal tissue than PANC1 xenografts (Fig. 5b). However, MRP4-overexpressing xenografts are less 
differentiated than mock tumors, as they reveal areas of solid tumor parenchyma with numerous mitotic and 
apoptotic figures. Immunostaining confirmed that these xenografts truly show elevated levels of MRP4 and an 
increased proliferative rate evidenced by intense MRP4 and Ki67 staining, respectively (p < 0.001). Regarding 
EGFR expression and localization, we found that MRP4-overexpressing tumors display a higher EGFR score 
compared to mock tumors (p < 0.01). EGFR upregulation upon MRP4 overexpression further sustains that 
MRP4 is associated with a poor prognosis, disease progression and higher aggressiveness in PDAC. Altogether, 
our findings support the hypothesis that MRP4 acts as a tumor booster and inspire the idea of targeting MRP4 
as a novel therapy in pancreatic cancer.
To determine whether MRP4 modulation affects the expression of EMT markers in PDAC, we evaluated 
vimentin and E-cadherin (CDH1) mRNA levels by qPCR in BxPC-3 clones. BxPC-3-MRP4 cells express sig-
nificant higher levels of vimentin and lower levels of E-cadherin compared to mock cells (Fig. 6a). We then 
investigated if MRP4 overexpression alters tumor spreading in vivo. BxPC-3-mock and BxPC-3-MRP4 cells both 
expressing GFP were inoculated into the tail vein of NSG mice. Four weeks later, the animals were humanely 
sacrificed, and the liver, kidneys and lungs were harvested to survey for CTC or metastatic foci. As shown in 
Table 1, incidence of metastases was significantly higher in the mice inoculated with MRP4-overexpressing cells 
compared to the mock group. Moreover, our data show that MRP4 overexpression augments metastatic incidence, 
especially to the liver, as all animals inoculated with BxPC-3-MRP4 cells exhibited hepatic macro-metastases at 
the end of the experiment (Table 1, Fig. 6b).
H&E staining and GFP immunostaining of liver, kidney and lung sections further verified the metastatic 
potential of BxPC-3-MRP4 cells and allowed the confirmation of small micro-metastases and CTC in the lungs 
(Fig. 6b; top). Specific immunostaining revealed that all metastatic foci were highly proliferative (Ki67) and con-
tinued expressing EGFR (Fig. 6b; bottom) as the parental xenografts displayed in Fig. 5b. Liver macro-metastases 
were numerous and evident at the end of the experiment (Fig. 6c) and FAC confirmed the presence of GFP + cells 
only in liver homogenates of BxPC-3-MRP4 inoculated mice (Fig. 6d). In fact, the BxPC-3-MRP4 group showed 
higher amount of hepatic metastatic foci per animal compared to the mock group (p < 0.001; Fig. 6e).
Endogenous GFP expression of BxPC-3 inoculated clones also allowed the visualization of renal and pul-
monary experimental metastases in cryostat sections of the respective organ tissues (Supplementary Fig. S1). 
Regarding renal colonization, mice inoculated with BxPC-3-MRP4 cells depicted higher amount of individual 
metastatic foci compared to the mock group (p < 0.01). As evidenced by the Bouin’s fluid fixation, lungs of both 
experimental groups showed numerous miniature pulmonary metastatic foci, which were difficult to quantify 
with the naked eye or even under a light microscope. FAC analysis confirmed that the % of GFP+ fluorescent 
cells in lung homogenates from the BxPC-3-MRP4 group was significantly higher than that of the mock group 
(p < 0.01). Altogether, our findings indicate that MRP4 overexpression enhances colonization of pancreatic cancer 
cells to the liver, kidneys, and lungs in NSG mice.
Discussion
In the present study we show that MRP4 is significantly upregulated in pancreatic cancer, PDAC cell lines and 
CTC from PDAC patients. MRP4 transcript levels inversely correlate with PDAC cell line differentiation grade, 
associate with an EMT signature, and determine PDAC tumor growth, migration and distant organ dissemina-
tion. Although more work is needed to validate our findings in PDAC samples, our results are the foundation to 
understand MRP4 association with PDAC aggressive behavior.
In our first approach, we were able to validate our previous results and test our hypothesis in an extensive 
PDAC cohort, using open access platforms. Our findings agree with those of Zhang et al., who examined by 
immunohistochemical staining 36 paired PDAC samples and reported that MRP4 protein levels are consistently 
augmented in pancreatic tumor samples compared to peritumor  tissues8. We now analyzed four different gene 
expression datasets, comprising more than 300 primary pancreatic tumors and 200 normal/adjacent pancreatic 
samples, and established that MRP4 upregulation occurs at a genomic level in pancreatic tumor tissues and in 
PDAC cell lines as well. The fact that we established that high MRP4 levels: (a) are typical of high-grade pan-
creatic cancer cell lines, (b) co-express with mesenchymal markers, (c) cause differential expression of genes 
related with chemotaxis, migration and adhesion, and (d) are upregulated in CTC from PDAC patients, led us 
to propose that MRP4 is coupled to cancer development and plays a role in the maintenance of an aggressive 
phenotype. In line with this, several observations from clinical studies have shown that ABC transporters confer 
chemoresistance to cancer stem cells and are linked to the progression of malignant  cancers21. In fact, MRP4 
expression significantly associates with poor clinical outcomes in neuroblastoma and has been consequently 
validated as a powerful independent predictor of clinical outcome in patients with this  tumor22,23. Altogether, 
our data suggest MRP4 could also be a potential prognostic biomarker in PDAC patients. Studies currently in 
progress, involving evaluation of MRP4 protein levels and subcellular localization by immunostaining in PDAC 
tissue microarrays will further validate MRP4 as an indicator predictor of clinical outcome in pancreatic cancer. 
For this, the relationship between MRP4 levels, tumor stage and patient outcome (chemo/radiotherapy response 
and overall survival) will be examined.
Few publications refer to the mechanisms responsible for induction of MRP4 expression in pancreatic can-
cer. MRP4 is upregulated in 5-FU-resistant pancreatic carcinoma  cells24, although the underlying mechanism 
of this induction is still unclear. Long-term treatment with cAMP-enhancing agents augments MRP4 mRNA 
and protein levels in several cell types, involving the EPAC/MEK route rather than the PKA/CREB  pathway25. 
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Studies from our laboratory confirmed that, in pancreatic cancer cells, intracellular cAMP upregulates MRP4 
through an Epac2/Rap1-mediated mechanism, whereas extracellular cAMP inhibits MRP4 promoter activity 
Figure 5.  MRP4 overexpression increases tumor growth in BxPC-3 xenografts. NSG mice were subcutaneously 
injected with BxPC-3-MRP4 or BxPC-3-mock as a control. Each group contained 5 animals and the data shows 
measurements of one of two experiments. (a; left) Tumors were measured with a caliper three times a week for 
32 days post-inoculation and tumor volume was calculated as described in “Materials and methods”. (a; middle) 
Representative pictures of the dissected xenografts of each group at the end of the experiment. (a; right) Tumor 
weight was measured with a scale after tumor dissection. (b) BxPC-3-mock and BxPC-3-MRP4 xenografts were 
processed for histological (H&E staining), MRP4, Ki67, and EGFR immunostaining evaluation. Nuclei were 
counterstained with hematoxylin. Representative images are shown. Cell number per field, proliferative index, 
MRP4 and EGFR scores were determined by H&E, Ki67, MRP4, and EGFR staining respectively, and are shown 
as bar plots (right). Data is shown as mean ± SEM. Statistics: Linear regression and Student´s t-test. ***p < 0.001, 
**p < 0.01, and *p < 0.05.
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Figure 6.  Effect of MRP4 overexpression upon BxPC-3 experimental metastasis. (a) Vimentin and E-cadherin 
(CDH1) transcript levels in BxPC-3-mock and BxPC-3-MRP4 cells, determined by qPCR as described 
in “Materials and methods”. Data is shown as mean ± SD of three measurements and the experiment was 
performed three times. (b) H&E staining, GFP, Ki67, and EGFR immunostaining of hepatic, renal, and 
pulmonary metastatic foci from BxPC-3-MRP4 inoculated mice. Nuclei were counterstained with hematoxylin. 
Representative images are shown. (c) Representative liver macro-metastases at the end of the experiment. (d) 
Representative comparison of GFP expression in liver homogenates, determined by FAC. (e) Number of hepatic 
metastatic foci per animal in each experimental group. Data is shown as mean ± SEM. Statistics: Student’s t-test. 
***p < 0.001, **p < 0.01, and *p < 0.05.
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by a MEK/ERK-mediated  pathway26. More recently, we described that an increase in intracellular cAMP levels 
induce MRP4 expression through the EPAC-PKA pathway in acute myeloid leukemia  models27. MAPK signal-
ing, through CREB1, NFκB, and EIF4E may also regulate MRP4 levels in human renal  cells28. Moreover, Wnt/β-
catenin signaling drives upregulation of MRP4 in human lung cancer cells, causing an increase in drug efflux 
and, thus, resistance to  cisplatin29. Interestingly, many of the pathways and main actors associated with MRP4 
transcriptomic regulation appeared to be dysregulated in our in silico analysis. Further research into the regula-
tory pathways that influence MRP4 expression specifically on pancreatic cancer is needed, as regulation of gene 
expression often depends on the cell system and context.
In this work, we selected PANC1 and BxPC-3 cell lines as models to study the role of MRP4 in pancreatic 
cancer progression. Phenotypically, both cell lines display differential expression levels of MRP4 and show distinct 
differentiation  grades30. Genetically, PANC1 present mutations in KRAS, p53 and p16, while BxPC-3 present 
mutations in p53, p16 and Smad4, but depict a wild type  KRAS31,32. We previously demonstrated that MRP4 
silencing in PANC1 cells reduces the proliferation rate in  culture9, and we now confirm a loss in tumorigenicity 
in vivo, as the incidence of palpable PANC1-MRP4sh xenografts significantly decreases compared to scramble 
xenografts. Conversely, MRP4 overexpression enhances BxPC-3 cell proliferation in culture compared to mock 
 cells9, and we now verify that these xenografts grow more and have an elevated proliferative index in vivo, 
determined by Ki67 immunostaining. The evaluation of clinically relevant histopathological parameters further 
sustains that MRP4 is associated with a poor prognosis and higher aggressiveness in PDAC. Regardless the simi-
larities and differences in the phenotype and genetic background of the PDAC cell lines used in our studies, these 
results validate our previous findings in an in vivo setting and indicate that MRP4 levels determine pancreatic 
tumor development, independently of KRAS status.
Additionally, the fact that in both cell models, MRP4 modulation alters EGFR score, which is associated with 
malignant transformation of pancreatic cancer and plays important roles in liver metastases and recurrence of 
human pancreatic  cancer12, indicates that targeting MRP4 could eventually serve as a novel therapeutic strategy 
in PDAC.
Since our bioinformatic discoveries establish that MRP4 expression is associated with a mesenchymal pheno-
type in PDAC cell lines and with a dysregulation of migration, chemotaxis and cell adhesion pathways in PDAC 
patients, we further explored whether MRP4 modulation affects cell migration and metastatic dissemination. 
Our data show that suppressing MRP4 in PANC1 cells decreases cell migration in culture, which is a key step 
in tumor invasion and eventual formation of metastatic foci. Moreover, the transcriptomic analysis of PANC1 
clones revealed that MRP4 silencing alters gene expression, mainly dysregulating pathways related to cell-to-cell 
interactions and focal adhesion, possibly compromising the invasive ability of PANC1 cells. MRP4sh2 cells show 
a lower expression of markers related to degradation and invasion of the extracellular matrix (ESRP2, PCOLCE2, 
LAMC3, MARCKS2, among others) and cell proliferation/survival (EGFL7, SESN2, CABLES1, MDK, among 
others), with a concomitant upregulation of genes associated with good prognosis in PDAC, such as  BMF33. 
Furthermore, quantification of specific EMT markers, vimentin and E-cadherin, revealed MRP4 overexpres-
sion causes a switch in the expression of these two key genes, indicating a transition towards a mesenchymal 
phenotype in phenotypically epithelial cells, such as BxPC-3. This may translate in an augmented aggressiveness 
and invasive capacity. However, this does not mean that MRP4 silencing causes the reverse process, inducing 
mesenchymal cells, such as PANC1, to an epithelial phenotype. We speculate this might partially explain why 
neither E-cadherin, vimentin or GATA6 expression were significantly altered in MRP4sh cells compared to 
scramble cells.
To study whether MRP4 affects tumor spreading, we inoculated GFP-BxPC-3 clones into the tail vein of 
NSG mice and evaluated the establishment of metastatic foci in various organs. Since MRP4-overexpressing 
BxPC-3 cells give rise to fast growing tumors, the animals must be euthanized before spontaneous metastases 
are detected. Although our experimental metastatic approach is a valuable model to study certain steps of the 
metastatic process, we are fully aware it bypasses invasion from the primary tumor and generates colonization 
rather than metastasis. However, this methodology, or directly injecting PDAC cells into the spleen of mice, is 
commonly used to evaluate pancreatic cancer  dissemination34,35. Together with the knowledge that CTC cells 
from PDAC patients express higher levels of MRP4 compared to primary tumor cells, and that silencing MRP4 
alters the expression of several CTC biomarkers, such as IL11, EBI3, VEGFA, and  ADGRG136, our findings 
suggest that an upregulation of the transporter could confer an adaptive advantage associated with disease 
progression in PDAC patients.
Regarding the tumor colonization sites attained in our experimental model, we identified hepatic, pulmo-
nary and renal metastatic foci, paralleling what happens in the clinic. Cancer cells originating in the pancreas 
preferentially metastasize to liver, lungs and  peritoneum37, supporting the notion that pancreatic tumors are 
highly specific regarding the metastatic  sites38,39. Also, as seen in our model, multiple foci sites are characteristic 
Table 1.  Experimental metastasis is higher in mice inoculated with BxPC-3-MRP4 cells compared to the 
mock group. Incidence of localized metastases in each experimental group. Statistics: Chi-square and Fisher 
exact test to analyze metastatic incidence among experimental groups. ***p < 0.001, **p < 0.01, and *p < 0.05.
Hepatic foci Renal foci Pulmonary foci
BxPC-3-mock 20% (2/10) 10% (1/10) 30% (3/10)
BxPC-3-MRP4 100% (11/11)*** 72.7% (8/11)** 81.8% (9/11)*
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of hepatic metastases, and patients with liver disease often show oligometastases when  diagnosed40. Both obser-
vations imply that our experimental approach resembles clinical findings and that it is a valuable tool to study 
PDAC metastatic dissemination.
Successful adhesion of tumor cells to the liver is not just a mechanical process but depends on specific interac-
tions between the hepatic microvasculature and the cancer  cells41. These interactions contribute to the metastasis 
efficacy and represent useful therapeutic targets for controlling tumor  dissemination42. Our data show that high 
levels of MRP4 confer a more aggressive and invasive phenotype to PDAC cells, although its actual role upon cell 
migration is still controversial, as it depends on the cell system  studied43–45. Also, it is still unclear whether MRP4 
affects cell motility due to accumulation of endogenous bioactive MRP4 substrates in the extracellular compart-
ment, such as cyclic nucleotides, prostaglandins, and  leukotrienes7,46–48, or due to regulation of cell cycle and 
cytoskeleton protein levels, such as vimentin, cadherins, integrins or F-actin49. Regarding tumor dissemination, 
suppression of MRP4 showed a marked decrease in spontaneous lung metastases compared to control cells in a 
basal breast cancer xenograft  model50. The authors propose MRP4 plays a crucial role in the microenvironment 
of the primary tumor, as it maintains high PGE2 levels which act in an autocrine or paracrine way and boost 
the metastatic potential and progression of the tumor. Regarding cyclic nucleotides, cAMP regulates a variety of 
signaling events that compose cell  migration51,52 and affect it in a biphasic  manner53. We recently demonstrated 
that modulation of MRP4 directly affects cAMP balance, determining the activation of EPAC/Rap1 signaling 
pathway, and impacting on PANC1 cell  proliferation9. Accordingly, EPAC1 is often overexpressed in pancreatic 
cell lines and tumor  samples54 and our in silico analysis showed that Rap1 pathway is dysregulated in MRP4 HE 
pancreatic carcinomas. Moreover, our RNAseq study revealed that numerous genes related to Arf6, Plexin-D1, 
Wnt, GPCR and PI3K/AKT cascades are differentially modulated upon MRP4 suppression and may account for 
MRP4sh loss in malignity. The fact that several dysregulated signaling pathways are shared in both bioinformatic 
analysis emphasizes our proposal that MRP4 levels are indeed associated with PDAC progression. Further studies 
should be performed to confirm the activation status of the mentioned pathways in MRP4sh2 and scramble cells 
and unravel the underlying mechanism by which MRP4 influences migration/invasive capacity in PDAC cells.
Also, as a multidrug transporter, MRP4 overexpression in tumor cells may confer resistance to anticancer 
agents. Notably, chemotherapeutic drugs which are commonly used in PDAC, such as gemcitabine and pacli-
taxel, are not MRP4  substrates55. However, some reports describe that MRP4 participates in the generation of 
chemoresistant phenotypes in  cancer56,57. Studies involving the evaluation of the sensitivity to different anticancer 
agents and MRP4 expression levels will shed some light upon MRP4 role in PDAC chemoresistance and could 
possibly identify promising therapeutic combinations for cancer treatment.
Overall, our findings indicate that MRP4 upregulation could represent an adaptive advantage associated 
with poor prognosis, evidenced by the co-expression of mesenchymal markers, higher cell proliferation, tumo-
rigenicity and invasiveness in PDAC models. Thus, we provide theoretical and experimental support for targeted 
treatment of pancreatic cancer by making an important contribution to the understanding of pancreatic tumor 
cell biology. Further studies on the structural and functional characterization of MRP4 may facilitate the design 
of alternative therapeutic strategies for this devastating disease.
Materials and methods
cell culture. PANC1 and BxPC-3 human pancreatic cancer cell lines were obtained from the American 
Type Culture Collection (ATCC, USA) and grown in Dulbecco’s Modified Eagle’s Medium (DMEM) or RPMI-
1640 (RPMI) medium (Sigma-Aldrich), respectively. PANC1-scramble, PANC1-MRP4sh1, PANC1-MRP4sh2, 
BxPC-3-mock, and BxPC-3-MRP4 cells were established and characterized in our  laboratory9. Medium was 
always supplemented with 10% fetal bovine serum (FBS; Natocor, Argentina) and 50 µg/mL gentamicin (Sigma-
Aldrich). All cell cultures were maintained at 37 °C in a humidified atmosphere with 5%  CO2. PANC1 clones 
were maintained with puromycin from Streptomyces alboniger (Sigma-Aldrich; 1 µg/mL) and BxPC-3 clones 
were maintained with hygromycin B (SelleckChem; 200 µg/mL). MRP4 modulation does not alter cell viability 
in neither of the studied PDAC cell lines and MRP4sh xenografts show the same apoptotic index as scramble 
tumors (data not shown).
Mice. Two-month-old male nude (Fundación Facultad de Ciencias Veterinarias, UNLP, Argentina) and 
NOD/LtSz-scid/IL-2Rgamma null mice (NSG; Jackson Labs, Bar Harbor, Maine, USA) were used (27 g ± 2 g). 
Mice were bred and maintained under specific pathogen-free conditions in filter-top boxes with a 12 h light/12 h 
dark cycles at the IBYME animal facility. All studies comply with the ARRIVE guidelines, were carried out in 
accordance with the UK Animals (Scientific Procedures) Act, 1986 and were performed according to protocols 
approved by the IBYME-CICUAL committee (014/2017).
In silico analysis of MRP4/ABCC4 expression. Differential expression analysis were performed using 
the Gene Expression Profiling Interactive Analysis (GEPIA)  server58 (https ://gepia .cance r-pku.cn/index .html), 
which is based on the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) project and 
five online datasets (GSE15471, GSE62452, GSE717296, GSE64557, and GSE18670) obtained from the Gene 
Expression Omnibus (GEO) database (https ://www.ncbi.nlm.nih.gov/geo). GEPIA dataset contains 171 nor-
mal and 179 tumor samples, GSE15471 contains 39 tumor and paired normal samples, GSE62452 contains 
61 normal and 69 tumor samples, GSE71729 contains 46 normal, 145 tumor samples and 17 pancreatic can-
cer cell lines, GSE64557 contains 9 PDAC cell lines, and GSE18670 contains 6 tumor and paired blood sam-
ples. As previously  reported9, a group of 178 patients with pancreatic cancer and follow-up data (https ://xena.
ucsc.edu) was classified into low or high MRP4 mRNA expression levels according to the StepMiner one-step 
 algorithm59. The analysis of differentially expressed genes among tumors with high MRP4 expression (n = 48; 
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HE) and low expression (n = 24; LE) was performed using the SAM test, with the Multi Experiment Viewer 
software (MeV v4.9). Functional enrichment analysis of dysregulated genes was performed with the  ClueGO60 
and  CluePediaCytoscape61 plugin based on Wikipathway, Reactome, KEGG and Gene Ontology (Go) databases.
Stable transfection of GFP-BxPC-3 expressing cells. The p6NST50 lentiviral particles were kindly 
provided by Dr. Caroline Lamb from Instituto de Biología y Medicina Experimental (IBYME) and infection 
of BxPC-3-mock and BxPC-3-MRP4 cells was achieved as previously  described62. Transfected clones express-
ing GFP were identified by fluorescence microscopy, selected with zeocin (InvivoGen; 500 μg/mL) and MRP4 
overexpression was controlled by western blot analysis. For in vivo inoculation, cells were harvested using 0.25% 
trypsin and 0.1% EDTA (MicroVet SRL) and washed by centrifugation with serum-free RPMI medium. High 
GFP-expressing clones were then sorted using a FACS Aria II (BD Biosciences) and injected by tail vein in NSG 
mice.
RNA isolation and quantitative real-time PCR (qPCR). Briefly, total RNA was isolated from plate 
cultured cells using Quick-Zol (Kalium Technologies) and cDNA libraries were constructed from 1 µg of total 
RNA (M-MLV 200 U/µL; Promega) following manufacturer’s instructions. For qPCR, HOT FIREPol’ EvaGreen 
qPCR Mix Plus (Solis Biodyne, Tartu, Estonia) was used in a 15 µL final volume reaction. The specific PCR 
primer pairs used to amplify mRNA for CDH1 and vimentin genes are listed: CDH1: Fw 5′-AAG TGC TGC AGC 
CAA AGA CAGA-3′ and Rv: 5′-AGG TAG ACC CAC CTC AAT CAT CCT C-3′; vimentin Fw: 5′-CCA GGC AAA 
GCA GGA GTC -3′ and Rv: 5′-CGA AGG TGA CGA GCC ATT -3′. Reactions were performed as follows: 95 °C for 
15 min, and 40 cycles of 95 °C for 15 s, 60 °C for 20 s and 72 °C for 30 s. Values plotted are the changes relative to 
control (ΔΔCt), which determines the fold increase in mRNA levels relative to the internal control β-actin (Fw: 
5′-GGA CTT CGA GCA AGA GAT GG-3′ and Rv: 5´-AGC ACT GTG TTG GCG TAC AG-3′). Biological triplicates 
were performed.
RNAsequencing (RNAseq) and RNAseq analysis of PANC1, PANC1-scramble and 
PANC1-MRP4sh clones. RNA concentration and integrity were measured on an Agilent 2100 Bioanalyzer 
(Agilent Technologies). mRNA from PANC1, PANC1-scramble and PANC1-MRP4sh2 cells was processed for 
directional RNAseq library construction using the TruSeq RNA Sample Preparation Kit v2 according to the 
manufacturer’s protocol. We performed 101-nt paired-end sequencing using an Illumina HiSeq2500 platform 
at Macrogen Core Facility and obtained about 30 million tags per sample. QC and alignment of the short-read 
sequences against the human reference genome (hg19) was performed using the  ShortRead63 and  Rsubread64 R/
Bioconductor (https ://bioco nduct or.org/) packages, respectively. Subsequently, the number of reads mapped to 
each gene on the basis of the UCSC.hg19.KnownGene database were counted, reported, and annotated using the 
GenomicFeatures, GenomicAlignments, and org.Hs.eg.db packages. Raw datasets have been submitted to NCBI 
GEO database (Supplementary Table  S2). To identify differentially expressed genes between PANC1 clones, 
we used the edgeR-test on the basis of the normalized number of reads mapped to each  gene65. Functional 
enrichment analyses were performed using the Enrichr  resource66 (https ://amp.pharm .mssm.edu/Enric hr) and 
 InnateDB67 (https ://www.innat edb.com) based on the list of dysregulated transcripts between scramble and 
MRP4sh cells (FDR < 0.05; Fold changes > 2). Data integration and visualization of differentially expressed tran-
scripts were done with R/Bioconductor and the MultiExperiment Viewer  software68. Supplementary Table S3 
condenses the top 10 down- and upregulated transcripts in MRP4sh cells compared to scramble cells. Differ-
ential expression was established according to the Log Fold Changes. The associated function for each tran-
script was obtained from Genecards (https ://www.genec ards.org) or Pub Med (https ://pubme d.ncbi.nlm.nih.
gov/22155 432).
Wound-healing assay. PANC1-scramble, PANC1-MRP4sh1 and PANC1-MRP4sh2 cells at exponential 
growth phase were seeded in 24-well plates at 1 × 105 cells/well. When full confluence was reached, cells were 
incubated overnight in serum-free DMEM medium for cell cycle synchronization. Wounds were made by scrap-
ing the monolayer with a 200 µL pipette tip and washed twice with PBS. Cells were then incubated for 48 h in 
1% FBS-supplemented medium. Images of the scratches were acquired using an Eclipse E200 (Nikon) micro-
scope at the beginning  (A0) and end  (Af) of the experiment and wound healing areas were quantified using the 
ImageJ software (National Institutes of Health, USA). Percentage decrease of initial scratch area was calculated 
as 100 × (A0 − Af)/A0.
In vivo assays. PANC1 and BxPC-3 clones at exponential growth phase were harvested using 0.25% trypsin 
and 0.1% EDTA (MicroVet SRL), and washed with PBS prior to injection. A total of 33 nude mice were ran-
domly divided into three groups (n = 11), each inoculated subcutaneously (7 × 106 cells in 100 μL DMEM) with 
either PANC1-scramble, PANC1-MRP4sh1 or PANC1-MRP4sh2. A total of 10 NSG mice (Jackson Labs, Bar 
Harbor and bread in IBYME facilities) were randomly divided into two groups (n = 5), each inoculated subcu-
taneously (2 × 106 cells in 100 μL RPMI) with either BxPC-3-mock or BxPC-3-MRP4 cells. Tumor growth was 
measured three times a week using a Vernier caliper, calculating tumor volumes according to: 4/3 × π × minor 
 radius2  ×  major radius. At the end of the experiments, mice were humanely euthanized by dislocation and 
tumors excised, weighed, fixed in 10% buffered formalin and embedded in paraffin for histological evaluation 
and immunohistochemical studies. For the experimental metastasis studies, single cell suspensions of GFP-
BxPC-3-mock or GFP-BxPC-3-MRP4 cells (5 × 105 in 100 μL RPMI) were injected by tail vein using a 29 gauge 
needle. All 21 NSG mice were monitored periodically and, after four weeks, the animals were humanely eutha-
nized by cervical dislocation and processed as mentioned.
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Murine tissue collection and analysis of metastatic burden. All major organs were observed 
directly, images were captured, and location and number of metastases were recorded for each mouse. At least 
one metastatic lesion needed to be present for an organ to be considered positive for metastases. Lungs, liver, and 
kidneys were removed and visually inspected. All organs were fixed in 10% buffered formalin and embedded in 
paraffin before sectioning and stained with hematoxylin and eosin (H&E) according to standard protocols. His-
tological examination of the tumor and organ sections was performed using an Eclipse E800 light microscope 
(Nikon) and images were acquired with the ACT-2U software (v1.7).
Fluorescence imaging of frozen sections. Resected lungs and kidneys were washed with PBS, fixed in 
cold 4% PFA for 48 h and then incubated in cold 20% sucrose for another 48 h. The organs were then embedded 
in OCT compound (Tissue-Tek) and immediately frozen to − 80 °C. Tissue serial sections (8 μm) were made 
with a Cryotome Ecryostat (Thermo) and counterstained with propidium iodide (PI, Sigma-Aldrich; 20 μg/mL). 
Images were acquired with an Olympus IX83 microscope and the Cell Sens Dimensions (Olympus) software.
Tissue dissociation and flow cytometry (FAC) sample preparation. Lung and liver pieces were 
minced with a scalpel and digested in 4 mL of enzymatic solution (trypsin: 2.5 mg/mL and collagenase type II 
[Gibco BRL]: 850 U/mL in PBS) at 37 °C for 1 h with gentle agitation. The homogenates were filtered with a 
70 μm nylon cell strainer to remove debris. The single cell suspensions were centrifuged for 5 min and fixed in 
4% PFA overnight, washed twice in FAC buffer (PBS with 1% BSA and 0.5% sodium azide) and resuspended in 
FAC buffer with PI 20 μg/mL to stain cells. FAC analysis was conducted using a FACS Canto II (BD Biosciences). 
Cells were excited by a blue 488 nm laser (Coherent Sapphire Solid State), and GFP cells were acquired in FL1 
channel (E detector) loaded with a 530/30 nm bandpass filter previously filtered with a 502 nm longpass dichroic 
mirror. List mode data were obtained from at least 30,000 cells and the % of GFP + cells in each homogenate was 
estimated. Different gates for exclusion of cell debris, duplets and quantification of GFP expression were made 
using the FlowJo 10 software (Tree Star, Ashland, OR, USA).
Immunohistochemistry. Immunohistochemistry (IHC) was performed as previously  described62, pri-
mary and secondary antibodies were used at 1/100 and 1/400 dilutions, respectively. Anti-Ki67 (ab-15580) and 
anti-EGFR (ab-52894) were purchased from Abcam, and anti-MRP4 (D1Z3W) and anti-GFP (D5.1 XR-P) were 
purchased from Cell Signaling Technology. IHC staining was reviewed in detail and a blind semi-quantitative 
scoring was performed by an experienced pathologist (MM). The intensity of the staining was graded as negative 
(0), weak (1), moderate (2), and strong (3). The staining score (scale: 0–300) results from the product between 
positivity (0–100%) and intensity.
Statistical analysis. All statistical analyses were performed using Prism 6.0 software (GraphPad, San 
Diego, CA, USA) and, unless otherwise indicated, were carried out by either implementing Student’s t-test, one-
way analysis of variance (ANOVA) followed by Tukey’s t-test or two-way ANOVA followed by Bonferroni’s mul-
tiple comparison test. Details of in silico data analyses, sample size and quantifications performed in this study 
are described in the corresponding “Materials and methods” section and figure legends. Experimental results are 
expressed as mean ± SEM and values of p < 0.05 were considered statistically significant.
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